Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2017 | ARASENS: Will combining different treatments improve prostate cancer survival?

Bertrand Tombal • 26 Mar 2017
EAU 2017
Prostate Cancer Abiraterone Darolutamide Docetaxel Enzalutamide
ARASENS

Bertrand Tombal, MD, PhD, Catholic University of Leuven, Leuven, Belgium, discusses the ARASENS trial for prostate cancer at the European Association of Urology (EAU) conference 2017 in London, UK. He highlights the three pillars of prostate cancer treatment: androgen deprivation therapy, androgen receptor suppression, and chemotherapy. Prof. Tombal introduces the hypothesis that combining these treatments will improve overall survival (OS), on which the Phase III ARASENS trial (NCT02799602) is based, and outlines the design of this study.

More from Bertrand Tombal

PSMA expression as a key predictor of response to PSMA lutetium therapy
1:38
PSMA expression as a key predictor of response to PSMA lutetium therapy
Bertrand Tombal • 20 Oct 2025
ENZARAD: ADT, radiotherapy and radical prostatectomy in prostate cancer
1:15
ENZARAD: ADT, radiotherapy and radical prostatectomy in prostate cancer
Bertrand Tombal • 20 Oct 2025
Emerging treatment strategies in castration-resistant prostate cancer
1:20
Emerging treatment strategies in castration-resistant prostate cancer
Bertrand Tombal • 20 Oct 2025
Optimal sequencing of therapies in metastatic prostate cancer
1:48
Optimal sequencing of therapies in metastatic prostate cancer
Bertrand Tombal • 20 Oct 2025

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
Background and rationale for the PROTEUS trial in HR LPC/LAPC
0:48
Background and rationale for the PROTEUS trial in HR LPC/LAPC
Mary-Ellen Taplin • 29 May 2026
Future directions in prostate cancer from the PROTEUS trial
1:08
Future directions in prostate cancer from the PROTEUS trial
Mary-Ellen Taplin • 29 May 2026
Prognostic model for rPFS in mCRPC incorporating ctDNA with established risk factors
1:42
Prognostic model for rPFS in mCRPC incorporating ctDNA with established risk factors
Susan Halabi • 29 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals